Table III.
Effect of CM administration on renal functions parameters and oxidative stress markers in the study population.
| A, CAD group (early CIN patients excluded) | |||||||
|---|---|---|---|---|---|---|---|
| Sampling time | Creatinine (mg/dl) | Urea (mg/dl) | GSH (µmol/g Hb) | TAC (mmol DPPH/L plasma) | TBARS (µmol/l) | Catalase (U/mg Hb) | Carbonyls (nmol/mg protein) |
| t=0 | 0.806±0.117 | 39.6±12.4 | 0.588±0.482 | 0.905±0.128 | 3.58±1.31 | 174±30.1 | 1.26±0.412 |
| t=1 h | 0.828±0.192 | 38.4±14.8 | 0.63±0.493 | 0.956±0.114b | 3.46±1.26 | 179±45.1 | 0.840±0.228b |
| t=4–6 h | 0.876±0.222 | 34.1±11.4a | 1.45±1.02c | 0.926±0.105 | 4.71±1.94a | 163±35.1a | 0.889± 0.248a |
| B, Control group | |||||||
| Sampling time | Creatinine (mg/dl) | Urea (mg/dl) | GSH (µmol/g Hb) | TAC (mmol DPPH/L plasma) | TBARS (µmol/l) | Catalase (U/mg Hb) | Carbonyls (nmol/mg protein) |
| t=0 | 1.06±0.190 | 42.8±23.2 | 1.91± 0.807 | 0.956± 0.150 | 7.32± 1.34 | 192± 67.8 | 0.793± 0.141 |
| t=1 h | 1.04±0.151 | 49.6±24.0 | 2.01±0.43 | 0.945±0.157 | 7.81±1.88 | 193±94.1 | 0.794± 0.128 |
| t=5–10 h | 0.839±0.242b | 39.8±14.9 | 2.13±1.14 | 0.933±0.161 | 8.06±3.26 | 223±108 | 0.785±0.180 |
Statistical significance compared to t=0
a
P<0.05
b
P<0.01
c
P<0.001. CAD, coronary artery disease; CIN, contrast induced nephropathy; CM, contrast medium; GSH, glutathione; TAC, total anti-oxidant activity; TBARS, thio-barbituric acid reactive species.